These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 9690698)

  • 1. Positron emission tomographic analysis of dose-dependent MDL 100,907 binding to 5-hydroxytryptamine-2A receptors in the human brain.
    Andrée B; Nyberg S; Ito H; Ginovart N; Brunner F; Jaquet F; Halldin C; Farde L
    J Clin Psychopharmacol; 1998 Aug; 18(4):317-23. PubMed ID: 9690698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [11C]MDL 100907, a radioligland for selective imaging of 5-HT(2A) receptors with positron emission tomography.
    Lundkvist C; Halldin C; Ginovart N; Nyberg S; Swahn CG; Carr AA; Brunner F; Farde L
    Life Sci; 1996; 58(10):PL 187-92. PubMed ID: 8602111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PET imaging of central 5-HT2A receptors with carbon-11-MDL 100,907.
    Ito H; Nyberg S; Halldin C; Lundkvist C; Farde L
    J Nucl Med; 1998 Jan; 39(1):208-14. PubMed ID: 9443763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brain 5-HT2A receptor occupancy of deramciclane in humans after a single oral administration--a positron emission tomography study.
    Kanerva H; Vilkman H; Någren K; Kilkku O; Kuoppamäki M; Syvälahti E; Hietala J
    Psychopharmacology (Berl); 1999 Jul; 145(1):76-81. PubMed ID: 10445375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time course of 5-HT2A receptor occupancy in the human brain after a single oral dose of the putative antipsychotic drug MDL 100,907 measured by positron emission tomography.
    Gründer G; Yokoi F; Offord SJ; Ravert HT; Dannals RF; Salzmann JK; Szymanski S; Wilson PD; Howard DR; Wong DF
    Neuropsychopharmacology; 1997 Sep; 17(3):175-85. PubMed ID: 9272484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation of the CNS penetration of a potent 5-HT2a receptor antagonist (MDL 100,907) and an active metabolite (MDL 105,725) using in vivo microdialysis sampling in the rat.
    Scott DO; Heath TG
    J Pharm Biomed Anal; 1998 May; 17(1):17-25. PubMed ID: 9608422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of a rat in vivo [(3)H]M100907 binding assay to determine a translatable measure of 5-HT(2A) receptor occupancy.
    Knauer CS; Campbell JE; Galvan B; Bowman C; Osgood S; Buist S; Buchholz L; Henry B; Wong EH; Shahid M; Grimwood S
    Eur J Pharmacol; 2008 Sep; 591(1-3):136-41. PubMed ID: 18593577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fenfluramine Reduces [11C]Cimbi-36 Binding to the 5-HT2A Receptor in the Nonhuman Primate Brain.
    Yang KC; Stepanov V; Martinsson S; Ettrup A; Takano A; Knudsen GM; Halldin C; Farde L; Finnema SJ
    Int J Neuropsychopharmacol; 2017 Sep; 20(9):683-691. PubMed ID: 28911007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended characterisation of the serotonin 2A (5-HT2A) receptor-selective PET radiotracer 11C-MDL100907 in humans: quantitative analysis, test-retest reproducibility, and vulnerability to endogenous 5-HT tone.
    Talbot PS; Slifstein M; Hwang DR; Huang Y; Scher E; Abi-Dargham A; Laruelle M
    Neuroimage; 2012 Jan; 59(1):271-85. PubMed ID: 21782029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetic analysis of the 5-HT2A ligand [11C]MDL 100,907.
    Watabe H; Channing MA; Der MG; Adams HR; Jagoda E; Herscovitch P; Eckelman WC; Carson RE
    J Cereb Blood Flow Metab; 2000 Jun; 20(6):899-909. PubMed ID: 10894173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A practical synthesis of the serotonin 5-HT2A receptor antagonist MDL 100907, its enantiomer and their 3-phenolic derivatives as precursors for [11C]labeled PET ligands.
    Ullrich T; Rice KC
    Bioorg Med Chem; 2000 Oct; 8(10):2427-32. PubMed ID: 11058037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [3H]MDL 100,907 labels 5-HT2A serotonin receptors selectively in primate brain.
    López-Giménez JF; Vilaró MT; Palacios JM; Mengod G
    Neuropharmacology; 1998 Sep; 37(9):1147-58. PubMed ID: 9833645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct comparison of [(18) F]MH.MZ and [(18) F] altanserin for 5-HT2A receptor imaging with PET.
    Hansen HD; Ettrup A; Herth MM; Dyssegaard A; Ratner C; Gillings N; Knudsen GM
    Synapse; 2013 Jun; 67(6):328-37. PubMed ID: 23390031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of LC/MS to assess brain tracer distribution in preclinical, in vivo receptor occupancy studies: dopamine D2, serotonin 2A and NK-1 receptors as examples.
    Chernet E; Martin LJ; Li D; Need AB; Barth VN; Rash KS; Phebus LA
    Life Sci; 2005 Dec; 78(4):340-6. PubMed ID: 16139310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile.
    Kehne JH; Baron BM; Carr AA; Chaney SF; Elands J; Feldman DJ; Frank RA; van Giersbergen PL; McCloskey TC; Johnson MP; McCarty DR; Poirot M; Senyah Y; Siegel BW; Widmaier C
    J Pharmacol Exp Ther; 1996 May; 277(2):968-81. PubMed ID: 8627580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Binding characteristics of the 5-HT2A receptor antagonists altanserin and MDL 100907.
    Kristiansen H; Elfving B; Plenge P; Pinborg LH; Gillings N; Knudsen GM
    Synapse; 2005 Dec; 58(4):249-57. PubMed ID: 16206185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of a tracer kinetic model for the quantification of 5-HT(2A) receptors in human brain with [(11)C]MDL 100,907.
    Hinz R; Bhagwagar Z; Cowen PJ; Cunningham VJ; Grasby PM
    J Cereb Blood Flow Metab; 2007 Jan; 27(1):161-72. PubMed ID: 16685260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PET analysis of the 5-HT2A receptor inverse agonist ACP-103 in human brain.
    Nordstrom AL; Mansson M; Jovanovic H; Karlsson P; Halldin C; Farde L; Vanover KE; Hacksell U; Brann MR; Davis RE; Weiner DM
    Int J Neuropsychopharmacol; 2008 Mar; 11(2):163-71. PubMed ID: 17708779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A definite measure of occupancy exposures, seeking with non-radiolabeled in vivo 5-HT2A receptor occupancy and in vitro free fractions.
    Bhyrapuneni G; Thentu JB; Palacharla VRC; Muddana N; Aleti RR; Ajjala DR; Nirogi R
    J Recept Signal Transduct Res; 2018 Aug; 38(4):359-366. PubMed ID: 30481094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Excitation of interneurons in piriform cortex by 5-hydroxytryptamine: blockade by MDL 100,907, a highly selective 5-HT2A receptor antagonist.
    Marek GJ; Aghajanian GK
    Eur J Pharmacol; 1994 Jul; 259(2):137-41. PubMed ID: 7957607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.